Insmed reported $-320443000 in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
DBV Technologies EUR -41758000 18.75M Jun/2025
Dynavax Technologies USD 21.22M 119.09M Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Insmed USD -320443000 64.77M Jun/2025
Novartis USD 4.53B 133M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Sarepta Therapeutics USD 153.64M 537.16M Jun/2025
Ultragenyx Pharmaceutical USD -114004000 35.77M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025